Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 7 de 7
Filter
Add more filters










Database
Language
Publication year range
1.
Int J Oral Maxillofac Surg ; 44(7): 921-8, 2015 Jul.
Article in English | MEDLINE | ID: mdl-25769221

ABSTRACT

To investigate the effect of the sequential delivery of bone morphogenetic proteins BMP-2 and BMP-7 on bone regeneration in rat calvarial defects (40 Sprague-Dawley rats, 8mm defect size), all animals were treated with a hydroxyapatite (HA)/tricalcium phosphate (TCP) bone graft covered with a collagen membrane. The experimental groups were as follows: (1) control group: unmodified collagen (no treatment); (2) BMP-2 group: 5 µg of BMP-2; (3) hep-BMP-7 group: 5 µg BMP-7 chemically bound to heparinized collagen; and (4) BMP-2/hep-BMP-7 group: 2.5 µg BMP-7 bound to heparinized collagen and subsequently treated with 2.5 µg BMP-2. Defect healing was examined at 2 and 8 weeks after surgery. The BMP-2 group showed the largest new bone area at week 2 (29.3 ± 7.3%; P = 0.009); new bone areas in the hep-BMP-7 and BMP-2/hep-BMP-7 groups were similar (11.8 ± 3.4% and 12.9 ± 5.71%, respectively; P = 0.917). After 8 weeks, the BMP-2/hep-BMP-7 group showed the largest new bone area (43.3 ± 6.2%), followed by the BMP-2 and hep-BMP-7 groups (P = 0.013). Accordingly, in comparison with single deliveries of BMP-2 and BMP-7, sequential delivery of BMP-2 and BMP-7 using a heparinized collagen membrane significantly induced new bone formation with a smaller quantity of BMP-2 in rat calvarial defects.


Subject(s)
Bone Morphogenetic Protein 2/administration & dosage , Bone Morphogenetic Protein 2/pharmacology , Bone Morphogenetic Protein 7/administration & dosage , Bone Morphogenetic Protein 7/pharmacology , Bone Regeneration/drug effects , Skull/surgery , Wound Healing/drug effects , Animals , Bone Substitutes/pharmacology , Collagen/pharmacology , Drug Delivery Systems , Durapatite/pharmacology , Osteogenesis/drug effects , Rats , Rats, Sprague-Dawley
2.
Allergy ; 70(6): 674-81, 2015 Jun.
Article in English | MEDLINE | ID: mdl-25703927

ABSTRACT

BACKGROUND: Periostin is a matricellular protein, and its synthesis in airway epithelial cells and lung fibroblasts is induced by interleukin (IL)-4 and IL-13. The significance of periostin as a biomarker of TH 2-induced airway inflammation, and (importantly) as a measure of the response to TH 2-targeted therapy, has recently been emphasized. We explored the relationship between periostin and airway hyperresponsiveness (AHR) in asthmatic children. METHODS: The study included 83 children aged 6-15 years in an asthmatic group (n = 54) and healthy controls (n = 29). We measured the periostin levels in serum and performed methacholine and mannitol provocation challenges. The responses to mannitol were expressed as the provocative dose causing a 15% fall in the FEV1 (the PD15 dose). RESULTS: Of the 54 subjects with asthma, all had positive methacholine bronchial provocation test (BPT) results and 38 had positive mannitol BPT results. Children with asthma had significantly higher periostin levels than controls [76.0 (65.0-91.8) vs 71.0 (57.5-80.0) ng/mL; P = 0.017]. Periostin levels were significantly correlated with both the methacholine PC20 and mannitol PD15 values. CONCLUSION: Serum levels of periostin, a new biomarker induced by IL-13, were higher in asthmatic children, and were associated with AHR to methacholine and mannitol.


Subject(s)
Asthma/blood , Bronchial Provocation Tests , Bronchoconstrictor Agents , Cell Adhesion Molecules/blood , Mannitol , Methacholine Chloride , Respiratory Hypersensitivity/blood , Adolescent , Asthma/physiopathology , Case-Control Studies , Child , Female , Forced Expiratory Volume , Humans , Male , Respiratory Hypersensitivity/chemically induced , Respiratory Hypersensitivity/physiopathology
3.
Cell Death Differ ; 20(8): 1055-67, 2013 Aug.
Article in English | MEDLINE | ID: mdl-23645206

ABSTRACT

ZNF313 encoding a zinc-binding protein is located at chromosome 20q13.13, which exhibits a frequent genomic amplification in multiple human cancers. However, the biological function of ZNF313 remains largely undefined. Here we report that ZNF313 is an ubiquitin E3 ligase that has a critical role in the regulation of cell cycle progression, differentiation and senescence. In this study, ZNF313 is initially identified as a XIAP-associated factor 1 (XAF1)-interacting protein, which upregulates the stability and proapoptotic effect of XAF1. Intriguingly, we found that ZNF313 activates cell cycle progression and suppresses cellular senescence through the RING domain-mediated degradation of p21(WAF1). ZNF313 ubiquitinates p21(WAF1) and also destabilizes p27(KIP1) and p57(KIP2), three members of the CDK-interacting protein (CIP)/kinase inhibitor protein (KIP) family of cyclin-dependent kinase inhibitors, whereas it does not affect the stability of the inhibitor of CDK (INK4) family members, such as p16(INK4A) and p15(INK4B). ZNF313 expression is tightly controlled during the cell cycle and its elevation at the late G1 phase is crucial for the G1-to-S phase transition. ZNF313 is induced by mitogenic growth factors and its blockade profoundly delays cell cycle progression and accelerates p21(WAF1)-mediated senescence. Both replicative and stress-induced senescence are accompanied with ZNF313 reduction. ZNF313 is downregulated during cellular differentiation process in vitro and in vivo, while it is commonly upregulated in many types of cancer cells. ZNF313 shows both the nuclear and cytoplasmic localization in epithelial cells of normal tissues, but exhibits an intense cytoplasmic distribution in carcinoma cells of tumor tissues. Collectively, ZNF313 is a novel E3 ligase for p21(WAF1), whose alteration might be implicated in the pathogenesis of several human diseases, including cancers.


Subject(s)
Carrier Proteins/physiology , Cell Cycle Checkpoints/physiology , Cellular Senescence/physiology , Cyclin-Dependent Kinase Inhibitor p21/physiology , Transcription Factors/physiology , Ubiquitin-Protein Ligases/physiology , Adaptor Proteins, Signal Transducing , Animals , Apoptosis/physiology , Apoptosis Regulatory Proteins , Cell Cycle/physiology , Cell Differentiation/physiology , Cell Line , Cell Line, Tumor , F-Box Proteins/physiology , Heterografts , Humans , In Vitro Techniques , Intracellular Signaling Peptides and Proteins/physiology , Male , Mice , Mice, Nude , Models, Animal , Neoplasm Proteins/physiology
4.
Neuroscience ; 235: 165-73, 2013 Apr 03.
Article in English | MEDLINE | ID: mdl-23376369

ABSTRACT

Estrogen receptors (ERs) play important roles in estrogen-mediated neuroprotection. However, their effects on blood-brain barrier (BBB) disruption with vasogenic edema after ischemic stroke have not been determined. We evaluated a role for ERß in the brain without effects in the peripheral reproductive organs for the amelioration of vasogenic edema following ischemic stroke. Transient focal ischemic stroke was induced in ovariectomized female C57BL/6 mice (age 10-11weeks) that were treated with the ERß-selective agonist diarylpropionitrile (DPN). BBB breakdown as determined by the extravasation of endogenous immunoglobulin G (IgG), vasogenic edema, and the infarct volume was significantly reduced by DPN compared to vehicle. Protein expressions of endothelial tight junction proteins (occludin and claudin-5) and the water channel protein aquaporin 4 in the ischemic cortex were not changed by DPN. However, protein levels of vascular endothelial growth factor (VEGF) and hypoxia-inducible factor 1α (HIF-1α), a transcription factor that increases VEGF expression, were significantly decreased in the ischemic cortex by DPN. These results suggest that ERß contributes to the reduction of vasogenic edema caused by BBB breakdown via the inhibition of HIF-1α and VEGF following ischemic stroke.


Subject(s)
Blood-Brain Barrier/pathology , Brain Ischemia/drug therapy , Brain Ischemia/pathology , Estrogen Receptor beta/agonists , Actins/metabolism , Animals , Aquaporin 4/metabolism , Blotting, Western , Brain Chemistry/physiology , Brain Edema/metabolism , Brain Edema/pathology , Claudin-5/metabolism , Female , Hypoxia-Inducible Factor 1, alpha Subunit/metabolism , Immunoglobulin G/metabolism , Infarction, Middle Cerebral Artery/pathology , Mice , Mice, Inbred C57BL , Nitriles/pharmacology , Occludin/metabolism , Ovariectomy , Propionates/pharmacology , Tight Junctions/metabolism , Vascular Endothelial Growth Factor A/metabolism
5.
Fitoterapia ; 80(1): 18-20, 2009 Jan.
Article in English | MEDLINE | ID: mdl-18832017

ABSTRACT

A chloroform fraction prepared from the sarcotesta of Ginkgo biloba showed potent inhibitory activity against vancomycin-resistant Enterococcus (VRE). The active compounds were elucidated to be 2-hydroxy-6-(8-pentadecenyl) salicylic acid (1) and 2-hydroxy-6-(10-heptadecenyl) salicylic acid (2) based on their spectral analysis. Compounds 1 and 2 showed significant antibacterial activities against VRE.


Subject(s)
Anti-Bacterial Agents/pharmacology , Enterococcus/drug effects , Ginkgo biloba , Plant Extracts/pharmacology , Salicylates/pharmacology , Anti-Bacterial Agents/chemistry , Anti-Bacterial Agents/isolation & purification , Ginkgo biloba/chemistry , Microbial Sensitivity Tests , Molecular Structure , Salicylates/chemistry , Salicylates/isolation & purification , Seeds , Vancomycin Resistance
6.
Phytomedicine ; 12(9): 648-55, 2005 Sep.
Article in English | MEDLINE | ID: mdl-16194052

ABSTRACT

This study describes a potent activity of Cnidium officinale Makino (Cnidii rhizoma) and Tabanus fulvus Meigan (Tabanus) as an inhibitor of high glucose-induced proliferation of glomerular mesangial cells (GMCs). Raising the ambient glucose concentration from 5.6 to 25 mM for 24 h caused a dramatic increase in [3H]thymidine incorporation, and these increases were attenuated by treatment of GMCs with the extracts of Cnidii rhizoma and Tabanus (2.5-20 microg/ml) in a dose-dependent manner. In contrast, extracts of Cnidii rhizoma or Tabanus (20 microg/ml) did not change the growth of GMCs cultured under normal glucose condition. To clarify the mechanism involved in anti-proliferative activity of these medicines, this study examined the effects of Cnidii rhizoma and Tabanus on high glucose-stimulated extracellular matrix (ECM) protein accumulation and transforming growth factor-beta1 (TGF-beta1) production. Exposure of GMCs to high glucose significantly stimulated the ECM protein, collagen and fibronectin, accumulation and TGF-beta1 secretion, and these changes were dramatically diminished by treatment of GMCs with extracts of Cnidii rhizoma or Tabanus (10 microg/ml). Taken together, these results indicate that Cnidii rhizoma and Tabanus inhibit the high glucose-induced GMC proliferation partially through suppressing the ECM accumulation and TGF-beta1 production, suggesting that these medicines may be a promising agent for treating the development and progression of diabetic glomerulopathy.


Subject(s)
Antineoplastic Agents, Phytogenic/pharmacology , Diabetic Nephropathies/prevention & control , Glomerular Mesangium/drug effects , Phytotherapy , Plant Extracts/pharmacology , Plants, Medicinal , Animals , Antineoplastic Agents, Phytogenic/administration & dosage , Antineoplastic Agents, Phytogenic/therapeutic use , Cell Proliferation/drug effects , Cnidium , Dose-Response Relationship, Drug , Enzyme-Linked Immunosorbent Assay , Glomerular Mesangium/cytology , Glucose , Humans , Korea , Male , Medicine, East Asian Traditional , Plant Extracts/administration & dosage , Plant Extracts/therapeutic use , Rats , Rats, Sprague-Dawley
7.
SELECTION OF CITATIONS
SEARCH DETAIL
...